{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T20:48:16Z","timestamp":1778014096972,"version":"3.51.4"},"reference-count":18,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2012,1,25]],"date-time":"2012-01-25T00:00:00Z","timestamp":1327449600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arthritis Care &amp; Research"],"published-print":{"date-parts":[[2012,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>To compare the characteristics of female versus male gout patients and assess urate\u2010lowering efficacy and safety of febuxostat or allopurinol treatment in women with gout.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This was a retrospective analysis of 4,101 hyperuricemic (serum urate [sUA] level \u22658.0 mg\/dl) gout subjects enrolled in 3 phase III comparative trials and randomized to receive placebo, febuxostat (40 mg, 80 mg, 120 mg, or 240 mg daily), or allopurinol (100 mg, 200 mg, or 300 mg daily, based on renal function). Baseline demographics and characteristics were summarized and compared between female and male subjects. Urate\u2010lowering efficacy, which was defined as the proportion of subjects with sUA levels &lt;6.0 mg\/dl at final visit, was assessed for all subjects and, among women, according to baseline renal function.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Female gout subjects (n = 226) were older with significantly higher rates of obesity and metabolic and cardiovascular comorbidities than their male counterparts. The percentage of female subjects with sUA levels &lt;6.0 mg\/dl at final visit was 0% in the placebo group, 54.3%, 85.1%, 81.0%, and 100.0% in the febuxostat 40 mg, 80 mg, 120 mg, and 240 mg groups, respectively, and 45.9% in the allopurinol group. Similar patterns of urate\u2010lowering efficacy rates were observed when stratified by renal function. Among all the female subjects, febuxostat 80 mg was significantly more efficacious than allopurinol (<jats:italic>P<\/jats:italic> &lt; 0.001). Rates of adverse events (AEs) were low. The most frequently reported AEs were upper respiratory tract infections, musculoskeletal\/connective tissue disorders, and diarrhea.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>These data suggest that febuxostat 80 mg may be more efficacious than commonly prescribed doses of allopurinol in female gout subjects with high rates of comorbidities.<\/jats:p><\/jats:sec>","DOI":"10.1002\/acr.20680","type":"journal-article","created":{"date-parts":[[2011,11,2]],"date-time":"2011-11-02T09:57:29Z","timestamp":1320227849000},"page":"256-261","source":"Crossref","is-referenced-by-count":25,"title":["Women with gout: Efficacy and safety of urate\u2010lowering with febuxostat and allopurinol"],"prefix":"10.1002","volume":"64","author":[{"given":"Saima","family":"Chohan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael A.","family":"Becker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia A.","family":"MacDonald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Solomon","family":"Chefo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert L.","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,1,25]]},"reference":[{"key":"e_1_2_8_2_2","first-page":"2403","article-title":"Epidemiology of gout: is the incidence rising?","volume":"29","author":"Arromdee E","year":"2002","journal-title":"J Rheumatol"},{"key":"e_1_2_8_3_2","first-page":"1582","article-title":"Increasing prevalence of gout and hyperuricemia over 10 years among older adults in a managed care population","volume":"31","author":"Wallace KL","year":"2004","journal-title":"J Rheumatol"},{"key":"e_1_2_8_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.23176"},{"key":"e_1_2_8_5_2","volume-title":"Health, United States, 2009: with special feature on medical technology","author":"National Center for Health Statistics","year":"2010"},{"key":"e_1_2_8_6_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-143-7-200510040-00009"},{"key":"e_1_2_8_7_2","first-page":"1646","article-title":"Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout","volume":"33","author":"Dalbeth N","year":"2006","journal-title":"J Rheumatol"},{"key":"e_1_2_8_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2004.10.031"},{"key":"e_1_2_8_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa050373"},{"key":"e_1_2_8_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.24209"},{"key":"e_1_2_8_11_2","doi-asserted-by":"publisher","DOI":"10.1186\/ar2978"},{"key":"e_1_2_8_12_2","doi-asserted-by":"publisher","DOI":"10.4065\/81.7.925"},{"key":"e_1_2_8_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780200320"},{"key":"e_1_2_8_14_2","doi-asserted-by":"publisher","DOI":"10.1159\/000180580"},{"key":"e_1_2_8_15_2","doi-asserted-by":"publisher","DOI":"10.1097\/00003246-199310000-00016"},{"key":"e_1_2_8_16_2","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1001\/archinte.1986.00360230161022","article-title":"The clinical spectrum of gouty arthritis in women","volume":"146","author":"Lally EV","year":"1986","journal-title":"Arch Intern Med"},{"key":"e_1_2_8_17_2","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1001\/archinte.1991.00400040074016","article-title":"Female gout: clinical spectrum and uric acid metabolism","volume":"151","author":"Puig JG","year":"1991","journal-title":"Arch Intern Med"},{"key":"e_1_2_8_18_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.051649"},{"key":"e_1_2_8_19_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.076182"}],"container-title":["Arthritis Care &amp; Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Facr.20680","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/acr.20680","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T14:23:13Z","timestamp":1759414993000},"score":1,"resource":{"primary":{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/10.1002\/acr.20680"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1,25]]},"references-count":18,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,2]]}},"alternative-id":["10.1002\/acr.20680"],"URL":"https:\/\/doi.org\/10.1002\/acr.20680","archive":["Portico"],"relation":{},"ISSN":["2151-464X","2151-4658"],"issn-type":[{"value":"2151-464X","type":"print"},{"value":"2151-4658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,1,25]]}}}